Asia Pacific C-Reactive Protein Testing Market Size & Outlook
The c-reactive protein testing market in Asia Pacific is expected to reach a projected revenue of US$ 1,378.2 million by 2033. A compound annual growth rate of 2% is expected of Asia Pacific c-reactive protein testing market from 2026 to 2033.
Thermo Fisher Scientific Inc, Roche Holding AG ADR, Danaher Corp, Quest Diagnostics Inc, Siemens Healthineers AG ADR, Abbott Laboratories, Merck KGaA, Zoetis Inc Class A, QuidelOrtho Corp, Horiba Ltd, Getein Biotech, Boditech Med, Randox, Aidian
Other key industry trends
In terms of revenue, Asia Pacific region accounted for 22.0% of the global c-reactive protein testing market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 1,378.2 million by 2033.
Asia Pacific is projected to grow at the fastest pace even if the global market is not marled by substantial development and growth. Growing geriatric population in the region, increasing incidence of chronic diseases, and rising number of research studies pertaining to CRP testing are factors that can be attributed to the market growth.
Moreover, supportive government policies, well-developed healthcare infrastructure, and collaborations among public-private market players are also driving the progressions in the market.
Furthermore, the study on weight gain trajectories associated with elevated C-reactive protein levels in Chinese adults is predicted to further drive the progressions in the market. This study was conducted by researchers at National Institute for Nutrition and Health, China Center for Disease Control in association with other institutions.
Asia Pacific C-reactive Protein Testing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to C-reactive Protein Testing Market Outlook will help companies and investors design strategic landscapes.
Immunoturbidimetric Assay was the largest segment with a revenue share of 49.3% in 2025.
Horizon Databook has segmented the Asia Pacific c-reactive protein testing market based on immunoturbidimetric assay, elisa, chemiluminescence immunoassay (clia ) covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific is projected to grow at the fastest pace even if the global market is not marled by substantial development and growth. Growing geriatric population in the region, increasing incidence of chronic diseases, and rising number of research studies pertaining to CRP testing are factors that can be attributed to the market growth.
Moreover, supportive government policies, well-developed healthcare infrastructure, and collaborations among public-private market players are also driving the progressions in the market.
Furthermore, the study on weight gain trajectories associated with elevated C-reactive protein levels in Chinese adults is predicted to further drive the progressions in the market. This study was conducted by researchers at National Institute for Nutrition and Health, China Center for Disease Control in association with other institutions.
Asia Pacific C-Reactive Protein Testing Market Assay Type Outlook (Revenue, USD Million , 2021-2033)
Immunoturbidimetric assay
ELISA
Chemiluminescence Immunoassay (CLIA )
Others
Asia Pacific C-Reactive Protein Testing Market Detection range Outlook (Revenue, USD Million , 2021-2033)
hs-CRP
Conventional CRP
cCRP
Asia Pacific C-Reactive Protein Testing Market Disease type Outlook (Revenue, USD Million , 2021-2033)
Cardiovascular Diseases
Cancer
Rheumatoid arthritis
Inflammatory bowel disease
Endometriosis
Lupus
Others
Asia Pacific C-Reactive Protein Testing Market End Use Outlook (Revenue, USD Million , 2021-2033)
Clinics
Hospitals
Laboratories
Assisted Living Healthcare Facilities
Home
Others
Reasons to subscribe to C-reactive Protein Testing Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of C-reactive Protein Testing Market Outlook databook
Our clientele includes a mix of C-reactive Protein Testing Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific C-reactive Protein Testing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific C-reactive Protein Testing Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific C-Reactive Protein Testing Market, 2021-2033 (US$M)